Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 266

1.

HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia.

Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, Sargent A, Wood J, Moore C, Cruickshank ME.

BJOG. 2008 Jul;115(8):1001-7. doi: 10.1111/j.1471-0528.2008.01748.x. Epub 2008 May 22.

2.

Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.

3.

Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up.

Bar-Am A, Gamzu R, Levin I, Fainaru O, Niv J, Almog B.

Gynecol Oncol. 2003 Oct;91(1):149-53.

PMID:
14529675
4.

High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.

Denise Zielinski G, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, Meijer CJ.

J Pathol. 2001 Oct;195(3):300-6.

PMID:
11673826
5.

Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.

Pretorius RG, Peterson P, Azizi F, Burchette RJ.

Am J Obstet Gynecol. 2006 Nov;195(5):1260-5.

PMID:
17074547
6.

Human papilloma virus testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia.

Almog B, Gamzu R, Kuperminc MJ, Levin I, Fainaru O, Niv J, Bar-Am A.

Gynecol Oncol. 2003 Mar;88(3):345-50.

PMID:
12648585
7.

HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.

Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders PJ, Risse EJ, Runsink AP, de Schipper FA, Meijer CJ.

Gynecol Oncol. 2003 Oct;91(1):67-73.

PMID:
14529664
8.

Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2.

Pajtler M, Milicić-Juhas V, Milojković M, Topolovec Z, Curzik D, Mihaljević I.

Coll Antropol. 2010 Mar;34(1):81-6.

PMID:
20432737
9.

High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing.

Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Garcia S, Campo E, Pahisa J, Ordi J.

Am J Obstet Gynecol. 2007 Oct;197(4):359.e1-6. Epub 2007 Aug 21.

PMID:
17714678
10.

Cervical cytology and HPV test in follow-up after conisation or LLETZ.

Ostojić DV, Vrdoljak-Mozetic D, Stemberger-Papić S, Finderle A, Eminović S.

Coll Antropol. 2010 Mar;34(1):219-24.

PMID:
20432754
11.

Use of human papillomavirus testing in the management of atypical glandular cells.

Schnatz PF, Sharpless KE, O'Sullivan DM.

J Low Genit Tract Dis. 2009 Apr;13(2):94-101. doi: 10.1097/LGT.0b013e318183a438.

PMID:
19387129
12.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

13.
14.

PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia.

Fambrini M, Penna C, Pieralli A, Bussani C, Fallani MG, Andersson KL, Scarselli G, Marchionni M.

Gynecol Oncol. 2008 Apr;109(1):59-64. doi: 10.1016/j.ygyno.2007.12.032. Epub 2008 Feb 5.

PMID:
18255129
15.

Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions.

Smart OC, Sykes P, Macnab H, Jennings L.

Aust N Z J Obstet Gynaecol. 2010 Apr;50(2):164-7. doi: 10.1111/j.1479-828X.2009.01132.x.

PMID:
20522074
16.

Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia.

Coupé VM, Berkhof J, Verheijen RH, Meijer CJ.

BJOG. 2007 Apr;114(4):416-24.

17.

Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia.

Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, Verheijen RH, Helmerhorst TJ.

Br J Cancer. 2001 Mar 23;84(6):796-801.

18.

Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia.

Aerssens A, Claeys P, Beerens E, Garcia A, Weyers S, Van Renterghem L, Praet M, Temmerman M, Velasquez R, Cuvelier CA.

Cytopathology. 2009 Feb;20(1):27-35. doi: 10.1111/j.1365-2303.2008.00567.x. Epub 2008 May 28.

PMID:
18510550
19.

Conservative approach to preneoplastic cervical lesions in postmenopause.

Vetrano G, Aleandri V, Ciolli P, Scardamaglia P, Pacchiarotti A, Verrico M, Carboni S, Corosu R.

Anticancer Res. 2008 Nov-Dec;28(6B):3941-4.

20.

[Importance of human papillomavirus (HPV) screening in the follow-up after CIN2-3 treatment].

Riethmuller D, Gabelle C, Ramanah R, Sautière JL, Prétet JL, Schaal JP, Kantelip B, Mougin C, Maillet R.

J Gynecol Obstet Biol Reprod (Paris). 2008 Jun;37(4):329-37. doi: 10.1016/j.jgyn.2007.12.012. French.

Items per page

Supplemental Content

Write to the Help Desk